Population prevalence of high dose paracetamol in dispensed paracetamol/opioid prescription combinations: An observational study

BMC Clinical Pharmacology

Volumn 12, Issue , 2012, Pages

  Clark, Roderick ^a   Fisher, Judith E ^a,b   Sketris, Ingrid S ^a   Johnston, Grace M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Pharmaceutical Services   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE; PARACETAMOL;

ADULT; AGED; ARTICLE; CANADA; DRUG MEGADOSE; FEMALE; HUMAN; LIVER TOXICITY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PREVALENCE;

ACETAMINOPHEN; AGED; ANALGESICS, OPIOID; DRUG PRESCRIPTIONS; DRUG TOXICITY; FEMALE; HUMANS; MALE; NOVA SCOTIA; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 84862255858     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-12-11     Document Type: Article

References (57)

1. Barozzi N, Tett SE. Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market. Clin Rheumatol 2009, 28(5):509-519. 10.1007/s10067-008-1077-8, 19132456.
2. , , , http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/label_stand_guide_ld-eng.php, .
3. Schilling A, Corey R, Leonard M, Eghtesad B. Acetaminophen: old drug, new warnings. Cleve Clin J Med 2010, 77(1):19-27. 10.3949/ccjm.77a.09084, 20048026.
4. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiodt FV, Ostapowicz G, Shakil AO, Lee WM, . Acute Liver Failure Study Group Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42(6):1364-1372. 10.1002/hep.20948, 16317692, Acute Liver Failure Study Group.
5. Bolesta S, Haber SL. Hepatotoxicity associated with chronic acetaminophen administration in patients without risk factors. Ann Pharmacother 2002, 36(2):331-333.
6. Claridge LC, Eksteen B, Smith A, Shah T, Holt AP. Acute liver failure after administration of paracetamol at the maximum recommended daily dose in adults. BMJ 2010, 341:c6764. 10.1136/bmj.c6764, 21127120.
7. Jickling G, Heino A, Ahmed SN. Acetaminophen toxicity with concomitant use of carbamazepine. Epileptic Disord 2009, 11(4):329-332.
8. Moling O, Cairon E, Rimenti G, Rizza F, Pristera R, Mian P. Severe hepatotoxicity after therapeutic doses of acetaminophen. Clin Ther 2006, 28(5):755-760. 10.1016/j.clinthera.2006.05.002, 16861097.
9. Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol 2010, 196:369-405. 10.1007/978-3-642-00663-0_12, 2836803, 20020268.
10. James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metabolism and Disposition 2003, 31(12):1499-1506. 10.1124/dmd.31.12.1499, 14625346.
11. McClain CJ, Price S, Barve S, Devalarja R, Shedlofsky S. Acetaminophen hepatotoxicity: An update. Curr Gastroenterol Rep 1999, 1(1):42-49. 10.1007/s11894-999-0086-3, 10980926.
12. Sabate M, Ibanez L, Perez E, Vidal X, Buti M, Xiol X, Mas A, Guarner C, Forne M, Sola R, Castellote J, Rigau J, Laporte JR. Paracetamol in therapeutic dosages and acute liver injury: causality assessment in a prospective case series. BMC Gastroenterol 2011, 11:80. 10.1186/1471-230X-11-80, 3150324, 21762481.
13. Myers RP, Li B, Fong A, Shaheen AA, Quan H. Hospitalizations for acetaminophen overdose: a Canadian population-based study from 1995 to 2004. BMC Public Health 2007, 7:143. 10.1186/1471-2458-7-143, 1931590, 17615056.
14. Myers RP, Li B, Shaheen AA. Emergency department visits for acetaminophen overdose: a Canadian population-based epidemiologic study (1997-2002). CJEM 2007, 9(4):267-274.
15. Lee WM, Squires RH, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: Summary of a workshop. Hepatology 2008, 47(4):1401-1415. 3381946, 18318440.
16. Bronstein AC, Spyker DA, Cantilena LR, Green JL, Rumack BH, Giffin SL. 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 2010, 48(10):979-1178.
17. Bond GR, Novak JE. The human and economic cost of paracetamol (acetaminophen) overdose. Pharmacoeconomics 1995, 8(3):177-181. 10.2165/00019053-199508030-00001, 10155615.
18. Fagan E, Wannan G. Reducing paracetamol overdoses. BMJ 1996, 313(7070):1417-1418. 10.1136/bmj.313.7070.1417, 2352977, 8973219.
19. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM US, . Acute Liver Failure Study Group Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137(12):947-954. Acute Liver Failure Study Group.
20. Khandelwal N, James LP, Sanders C, Larson AM, Lee WM, . Acute Liver Failure Study Group Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 2011, 53(2):567-576. 10.1002/hep.24060, 3208905, 21274877, Acute Liver Failure Study Group.
21. , , , http://webprod.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp, .
22. Kobe B. Anonymous is acetaminophen safe? Accidental overdoses are common, but avoidable. Mayo Clin Womens Healthsource 2010, 14(1):1-2.
23. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007, 102(11):2459-2463. 10.1111/j.1572-0241.2007.01388.x, 17608778.
24. IMS Institute for Healthcare Informatics The Use of Medicines in the United States 2011, , , IMS Institute for Healthcare Informatics.
25. Campeau L. Top Rx drugs of 2010 2011, , .
26. Fishman SM, Gilson AM. Commentary to Michna et al.: The elephant in the room: hydrocodone/acetaminophen combination compounds and the substitution effect. Pain Med 2010, 11(3):379-381.
27. Ho V, Stewart M, Boyd P. Cholestatic hepatitis as a possible new side-effect of oxycodone: a case report. J Med Case Reports 2008, 2:140.
28. Michna E, Duh MS, Korves C, Dahl JL. Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Med 2010, 11(3):369-378. 10.1111/j.1526-4637.2010.00811.x, 20447306.
29. Anonymous Summary Minutes of the Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee 2009, , , Anonymous.
30. Anonymous Joint Meeting of the Drug Safety and Risk Management Advisory Committee with the Anesthetic and Life Support Drugs Advisory Committee and the Nonprescription Drugs Advisory Committee: Meeting Announcemen 2009, , , Anonymous.
31. Mort JR. High dose acetaminophen in narcotic combinations: should there be concern?. S D Med 2008, 61(8):294-295.
32. Albertson TE, Walker VM, Stebbins MR, Ashton EW, Owen KP, Sutter ME. A population study of the frequency of high-dose acetaminophen prescribing and dispensing. Ann Pharmacother 2010, 44(7-8):1191-1195.
33. Minister of Justice, Government of Canada Controlled Drugs and Substances Act. S.C 1996, 19. , , Minister of Justice, Government of Canada.
34. Nova Scotia Prescription Monitoring Program Nova Scotia Prescription Monitoring Program Operational Policies. Nova Scotia Prescription Monitoring Program: Policy and Reference Materials 2008, 17-21. Nova Scotia Prescription Monitoring Program, Nova Scotia, Nova Scotia Prescription Monitoring Program.
35. http://www.nspmp.ca/history.php, .
36. http://www.whocc.no/ddd/definition_and_general_considera/, .
37. http://cansim2.statcan.ca/cgi-win/cnsmcgi.exe?Lang=E&CNSM-Fi=CII/CII_1-eng.htm, .
38. http://www.gov.ns.ca/health/msi/eligibility.asp, .
39. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955, 11(3):375-386.
40. 2005, 132. Regulations Act. R.S., c. 393, s. 1, Province of Nova Scotia,
41. Mort JR, Shiyanbola OO, Ndehi LN, Xu Y, Stacy JN. Opioid-paracetamol prescription patterns and liver dysfunction: a retrospective cohort study in a population served by a US health benefits organization. Drug Saf 2011, 34(11):1079-1088. 10.2165/11593100-000000000-00000, 21981435.
42. Buckwalter JA, Martin JA. Osteoarthritis. Adv Drug Deliv Rev 2006, 58(2):150-167. 10.1016/j.addr.2006.01.006, 16530881.
43. Li C, Martin BC. Trends in emergency department visits attributable to acetaminophen overdoses in the United States: 1993-2007. Pharmacoepidemiol Drug Saf 2011, 20(8):810-818. 10.1002/pds.2103, 21796717.
44. , , , http://www.imshealth.com/deployedfiles/imshealth/Global/Americas/North%20America/Canada/StaticFile/Top10DispensedTherapeutic_En_11.pdf, .
45. MacDonald N, MacLeod SM. Has the time come to phase out codeine?. CMAJ 2010, 182(17):1825. 10.1503/cmaj.101411, 2988526, 20921244.
46. Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, Carleton B, Hayden MR, Madadi P, Koren G. More Codeine Fatalities After Tonsillectomy in North American Children. Pediatrics 2012, 129(5):e1343-e1347. 10.1542/peds.2011-2538, 22492761.
47. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I, Brockmoller J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007, 7(4):257-265. 10.1038/sj.tpj.6500406, 16819548.
48. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008, 83(2):234-242. 10.1038/sj.clpt.6100406, 17971818.
49. Krenzelok EP. The FDA Acetaminophen Advisory Committee Meeting - what is the future of acetaminophen in the United States? The perspective of a committee member. Clin Toxicol (Phila) 2009, 47(8):784-789.
50. Furlan AD, Reardon R, Weppler C. National Opioid Use Guideline Group: Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ 2010, 182(9):923-930. 10.1503/cmaj.100187, 2882451, 20439443.
51. National Opioid Use Guideline Group (NOUGG) Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain© 2010 2010, 5-6. National Opioid Use Guideline Group (NOUGG), , 3215603, 22084456, National Opioid Use Guideline Group (NOUGG).
52. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2011/2011_05-eng.php, .
53. Prior MJ, Cooper K, Cummins P, Bowen D. Acetaminophen availability increases in Canada with no increase in the incidence of reports of inpatient hospitalizations with acetaminophen overdose and acute liver toxicity. Am J Ther 2004, 11(6):443-452. 10.1097/01.mjt.0000140217.48324.e3, 15543083.
54. Tarantino G, Conca P, Basile V, Gentile A, Capone D, Polichetti G, Leo E. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007, 37(6):410-415. 10.1111/j.1872-034X.2007.00072.x, 17539815.
55. Tarantino G, Di Minno MN, Capone D. Drug-induced liver injury: is it somehow foreseeable?. World J Gastroenterol 2009, 15(23):2817-2833. 10.3748/wjg.15.2817, 2698999, 19533803.
56. Barshop NJ, Capparelli EV, Sirlin CB, Schwimmer JB, Lavine JE. Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011, 52(2):198-202. 10.1097/MPG.0b013e3181f9b3a0, 3059772, 21240014.
57. Graham GG, Day RO, Graudins A, Mohamudally A. FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?. Inflammopharmacology 2010, 18(2):47-55. 10.1007/s10787-010-0036-6, 20213329.